Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death-1 (PD1, PD-1)”

245 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 245 results

Early research (Phase 1)Ended earlyNCT03739138
What this trial is testing

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Who this might be right for
Advanced Solid Tumors
Merck Sharp & Dohme LLC 30
Testing effectiveness (Phase 2)Study completedNCT02853344
What this trial is testing

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 275
Early research (Phase 1)Active Not RecruitingNCT05853367
What this trial is testing

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Who this might be right for
Metastatic Solid TumorsAdvanced Solid Tumors
Merck Sharp & Dohme LLC 95
Testing effectiveness (Phase 2)Active Not RecruitingNCT06041802
What this trial is testing

Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Who this might be right for
Squamous Cell Carcinoma
Merck Sharp & Dohme LLC 19
Early research (Phase 1)Study completedNCT03111992
What this trial is testing

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 26
Large-scale testing (Phase 3)Study completedNCT03833167
What this trial is testing

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

Who this might be right for
Carcinoma, Squamous Cell
Merck Sharp & Dohme LLC 450
Large-scale testing (Phase 3)Ended earlyNCT04246177
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 480
Testing effectiveness (Phase 2)Looking for participantsNCT07252739
What this trial is testing

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Who this might be right for
Malignant Neoplasm
Merck Sharp & Dohme LLC 140
Testing effectiveness (Phase 2)Study completedNCT04799639
What this trial is testing

Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer

Who this might be right for
Cervical CancerChemotherapy EffectProgrammed Cell Death 1 Receptor / Antagonists & Inhibitors+1 more
Sun Yat-sen University 47
Testing effectiveness (Phase 2)UnknownNCT03171220
What this trial is testing

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

Who this might be right for
Advanced Malignant Solid Tumor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 40
Large-scale testing (Phase 3)Study completedNCT03517449
What this trial is testing

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Who this might be right for
Endometrial Neoplasms
Eisai Inc. 827
Large-scale testing (Phase 3)UnknownNCT05661240
What this trial is testing

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd 348
Large-scale testing (Phase 3)Active Not RecruitingNCT03765918
What this trial is testing

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Who this might be right for
Head and Neck Neoplasms
Merck Sharp & Dohme LLC 714
Large-scale testing (Phase 3)Study completedNCT03713593
What this trial is testing

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

Who this might be right for
Carcinoma, Hepatocellular
Merck Sharp & Dohme LLC 794
Testing effectiveness (Phase 2)Study completedNCT02331368
What this trial is testing

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Michigan Rogel Cancer Center 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07457177
What this trial is testing

Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL

Who this might be right for
NK T-Cell Lymphoma
LIANG WANG 40
Testing effectiveness (Phase 2)Study completedNCT03825510
What this trial is testing

Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect

Who this might be right for
Metastatic Nonsmall Cell Lung CancerNon Small Cell Lung Cancer
Crozer-Keystone Health System 3
Early research (Phase 1)Study completedNCT01295827
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)

Who this might be right for
Cancer, Solid Tumor
Merck Sharp & Dohme LLC 1,260
Large-scale testing (Phase 3)Study completedNCT04889118
What this trial is testing

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

Who this might be right for
Malignant Melanoma
Merck Sharp & Dohme LLC 131
Large-scale testing (Phase 3)Study completedNCT03783078
What this trial is testing

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

Who this might be right for
Merkel Cell Carcinoma
Merck Sharp & Dohme LLC 55
Next Page